PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PTC Therapeutics reports robust earnings, faces data release delays

PTC Therapeutics demonstrated strong financial performance and revenue growth in Q4 2022, setting a positive trajectory for 2023.
While facing challenges such as data release delays and regulatory engagements, the company's innovative pipeline and commercial successes position it well for future opportunities.
With upcoming data readouts, regulatory discussions, and market expansion initiatives, PTC is poised to navigate challenges and leverage opportunities for continued growth and impact.

PTC Therapeutics achieves record revenue, faces regulatory challenges and growth opportunities

PTC Therapeutics reported strong financial performance in Q1 2023, with a clear path towards achieving revenue targets. While facing challenges such as regulatory interactions and data expectations, the company is leveraging opportunities in upcoming study results and strategic initiatives to drive growth and market differentiation.

PTC Therapeutics reports strong Q2 revenue and advances pipeline

PTC Therapeutics showcased robust financial performance, positive trial outcomes, and strategic cost-saving measures in Q2 2023.
The company's strong revenue growth, global expansion plans, and pipeline advancements position it for sustained success.
Challenges include addressing analyst inquiries, navigating regulatory pathways, and ensuring market access post-2024.
Opportunities in product launches, regulatory activities, and strategic partnerships offer avenues for continued growth and innovation.

PTC Therapeutics reports robust Q3 earnings and strategic growth plans

PTC Therapeutics demonstrated strong financial performance and strategic partnerships in Q3 2023 earnings call.
The company's focus on pipeline advancement, commercial growth, and regulatory strategies positions it for future success.
While facing challenges in regulatory compliance and product comparability, PTC Therapeutics is leveraging opportunities for revenue growth and market expansion.

PTC Therapeutics posts robust Q4 earnings amidst regulatory challenges

PTC Therapeutics delivered strong financial performance in Q4 2023, driven by revenue growth and transformative gene therapy results, despite challenges from the CHMP opinion.
The company's strengths lie in its solid balance sheet, positive community feedback, and FDA alignment on registration programs, positioning it for future growth and approvals.
Opportunities abound in the launch of sepiapterin, accelerated approval discussions with the FDA, and promising programs for FA and ALS, signaling a positive outlook for PTC.

PTC Therapeutics reports robust Q1 performance amidst regulatory milestones

PTC Therapeutics demonstrated strong financial and operational performance in Q1 2024, driven by revenue growth and regulatory progress.
While facing challenges such as delays in European market access and regulatory complexities, the company remains focused on key therapeutic advancements.
Opportunities lie in upcoming clinical results, potential market expansions, and strategic regulatory pathways for accelerated product approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

SOUTH PLAINFIELD, N.J. , April 13, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, April 27, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results

Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced that he is stepping down after 25 years.

PTC Therapeutics Announces CEO Stuart Peltz Is Resigning

- Chief Operating Officer Matthew Klein, M.D., M.S., F.A.C.S.

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Kylie O'Keefe - Chief Commercial Officer Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Brian Abrahams - RBC Joseph Thome - Cowen David Lebowitz - Citi Kelly Shi - Jefferies Tazeen Ahmad - Bank of America Gena Wang - Barclays Mike Riad - Morgan Stanley Paul Choi - Goldman Sachs Danielle Brill - Raymond James Operator Good day, and welcome to the PTC Therapeutics Fourth Quarter 2022 Corporate Update and Financial Results Call. At this time, all participants are in a listen-only mode.

PTC Therapeutics, Inc. (PTCT) Q4 2022 Earnings Call Transcript

– 2022 total revenue of $699 million, representing 30% year-over-year growth,  or $740 million and 37% growth at CER* – – Guidance for full-year 2023 total revenue of $940 million to $1 billion reaffirmed – – Four important study readouts expected in first half of 2023, three of them registration-directed – SOUTH PLAINFIELD, N.J. , Feb. 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2022.

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2022 financial results and provide an update on the company's business and outlook on Tuesday, Feb. 21, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J., Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation.

PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation

PTCT is a commercial stage small cap surviving on a timely loan. Their revenue stream is overdependent on one franchise.

PTC Therapeutics: Overdependence On One Asset, Poor Cash Management

- Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Jan. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.

NICE Recommends Reimbursement for Translarna™

- 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives – - Submissions Due March 17, 2023 - SOUTH PLAINFIELD, N.J. , Jan. 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program.

PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?

-  ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth – -  $940 million - $1.0 billion 2023 total revenue guidance – -  Results from three registration-directed clinical trials expected in 2023 – -  One additional registration-directed clinical trial expected to initiate in 2023 – SOUTH PLAINFIELD, N.J. , Jan. 9, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P.

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating PTC Therapeutics, Inc. (NASDAQ: PTCT) on behalf of the company's long-term investors.The investigation seeks to determine whether PTC has issued false and misleading statements and/or failed to disclose material facts to its investors, thereby violating the securities laws and causing harm to the company's shareholders.PTC shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.

Kaskela Law LLC Announces Investigation of PTC Therapeutics, Inc. (PTCT) and Encourages Long-Term PTCT Investors to Contact the Firm

SOUTH PLAINFIELD, N.J. , Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P.

PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference

New York, New York--(Newsfile Corp. - December 5, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own PTCT please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245.

Moore Kuehn, PLLC Encourages Investors of PTC Therapeutics, Inc. to Contact Law Firm

Coupa Software

Hive Blockchain Technologies Ltd

Lyft

Marathon Digital Holdings

Opendoor

Zillow

While the concept of Nasdaq stocks to sell won't resonate too kindly with generally optimistic Americans, it's become a reality. It's not just about the fact that on a year-to-date basis, the benchmark S&P 500 index still trades in negative territory.

7 Nasdaq Stocks to Sell Before They Plunge in 2023

- First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil.

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

- Upstaza™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent European Union authorization - - AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD, N.J. , Nov. 17, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.

Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA

Altra Industrial Motion

Carvana

Generac Holdings

Maravai LifeSciences Holdings

Norwegian Cruise Line

Olaplex Holdings

Vaxcyte

Patterson-UTI Energy

Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.

These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022

The registration-directed phenylketonuria study results are anticipated by the end of the quarter. Management claims there are about 58,000 PKU patients globally that they can target by 2030.

PTC Therapeutics: PKU Trial News Likely To Shore Up Share Price

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why PTC Therapeutics (PTCT) is Poised for a Turnaround After Losing 23.4% in 4 Weeks

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Kylie O'Keefe - SVP, Head of Global Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Joseph Thome - Cowen Alexander Xenakis - Truist Raju Prasad - William Blair Gena Wang - Barclays Danielle Brill - Raymond James Kelly Shi - Jefferies Judah Frommer - Credit Suisse Tazeen Ahmad - Bank of America Operator Hello. Thank you for standing by.

News for PTC Therapeutics Stock (PTCT)